liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke
Linköping University, Department of Medical and Health Sciences, Division of Health Care Analysis. Linköping University, Faculty of Medicine and Health Sciences.
Sahlgrenska Academy, University of Gothenburg.
Sahlgrenska Academy, University of Gothenburg.
University of Umeå, Sweden; Danderyd Hospital Karolinska Institutet, Sweden, Sweden.
Show others and affiliations
2016 (English)In: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 86, no 11, 1053-1059 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To evaluate the cost-effectiveness of adding endovascular thrombectomy to standard care in patients with acute ischemic stroke.

METHODS: The cost-effectiveness analysis of endovascular thrombectomy in patients with acute ischemic stroke was based on a decision-analytic Markov model. Primary outcomes from ESCAPE, Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA), Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT), and Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) along with data from published studies and registries were used in this analysis. We used a health care payer perspective and a lifelong time horizon to estimate costs and effects.

RESULTS: The model showed that adding thrombectomy with stent retrievers to guideline-based care (including IV thrombolysis) resulted in a gain of 0.40 life-years and 0.99 quality-adjusted life-years along with a cost savings of approximately $221 per patient. The sensitivity analysis showed that the results were not sensitive to changes in uncertain parameters or assumptions.

CONCLUSIONS: Adding endovascular treatment to standard care resulted in substantial clinical benefits at low costs. The results were consistent throughout irrespective of whether data from ESCAPE, EXTEND-IA, MR CLEAN, REVASCAT, or SWIFT PRIME were used in this model.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2016. Vol. 86, no 11, 1053-1059 p.
National Category
Health Care Service and Management, Health Policy and Services and Health Economy
Identifiers
URN: urn:nbn:se:liu:diva-126429DOI: 10.1212/WNL.0000000000002439ISI: 000371887200012PubMedID: 26873954OAI: oai:DiVA.org:liu-126429DiVA: diva2:914537
Note

Funding agencies: Dental and Pharmaceutical Benefits Agency

Available from: 2016-03-24 Created: 2016-03-24 Last updated: 2016-05-30

Open Access in DiVA

The full text will be freely available from 2017-02-12 15:14
Available from 2017-02-12 15:14

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Aronsson, MattiasLevin, Lars-Åke
By organisation
Division of Health Care AnalysisFaculty of Medicine and Health Sciences
In the same journal
Neurology
Health Care Service and Management, Health Policy and Services and Health Economy

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 156 hits
ReferencesLink to record
Permanent link

Direct link